Teva Pharmaceutical Industries Ltd. TEVA announced that its anti-calcitonin gene-related peptide (“CGRP”) injection, Ajovy, was granted marketing approval by the European Commission for prophylaxis of ...

CGRP antagonists are a new class of drugs designed to prevent migraine headaches by targeting a key molecule involved in pain transmission. Calcitonin gene-related peptide (CGRP) monoclonal antibodies ...

PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals USA, Inc., an affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the autoinjector device for AJOVY ® ...

Aiming to break into a three-way battle among large drugmakers in the brand-new CGRP migraine class, tiny Biohaven Pharmaceutical has released detailed data for its own candidate, which one group of ...

Dublin, Oct. 19, 2023 (GLOBE NEWSWIRE) -- The "Global CGRP Inhibitor Market (2023 Edition): Analysis By Treatment (Preventive, Acute), Route of Administration (Oral, Nasal, Intravenous), By End-User, ...

Most patients with migraine are women, and this observation is reflected in clinical studies. A pharmacologist and a neurologist from the United States argue that the efficacy of calcitonin ...